Fundraising Fox
/Companies
Sign in

Spyre Therapeutics

NASDAQ: SYRE

2 known investors

Find your way into Spyre Therapeutics

Sign up to see every warm intro you have to Spyre Therapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Spyre Therapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Spyre develops and commercializes treatments for a broad range of diseases focused on improving patient outcomes.

BiotechHealthtechMedical Devices

Founders & leadership

CTCameron Turtle
Cameron TurtleChief Executive OfficerCameron Turtle is Chief Executive Officer of Spyre Therapeutics, which develops antibody-based treatments for autoimmune diseases. He previously served as Chief Strategy Officer at BridgeBio Pharma, worked as a consultant at McKinsey & Company, and holds a DPhil from the University of Oxford and a BS from the University of Washington.

Investors · 2

Aisling Capitallisted by Aisling CapitalNew York

How we know: Aisling Capital's portfolio page · Not right? Tell us

Valuation · disclosed

Disclosed events
$129.3Mvaluation at IPOApr 2016 · $10.00/share · 424B4
filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Related companies · 1

Sarepta TherapeuticsSarepta develops precision genetic medicines for people with rare diseases, with a focus on rare neuromuscular conditions. The company also runs an investigator-initiated studies program that funds independent clinical and non-clinical research in its therapeutic areas.

Companies working in the same space as Spyre Therapeutics.

Acquisitions · 1

Early investors' stakes continue via these deals
Aeglea Biotherapeutics

Spyre Therapeutics develops monoclonal antibodies with extended half-lives targeting inflammatory bowel disease and rheumatic conditions including rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. The company is advancing single-agent and combination antibody therapies designed to enable less frequent subcutaneous dosing while addressing unmet treatment needs in these immune-mediated diseases.

Frequently asked questions

What does Spyre Therapeutics do?
Spyre develops and commercializes treatments for a broad range of diseases focused on improving patient outcomes.
Who are Spyre Therapeutics's investors?
Spyre Therapeutics's investors include Access Biotechnology, Aisling Capital.